Anaphylaxis — Recognition & Epinephrine First

Key Points

• Anaphylaxis is life‑threatening.
• give intramuscular epinephrine immediately in the mid‑anterolateral thigh, repeat as needed, and manage airway/respiration/circulation with adjuncts and observation.
• Adult: 0.3–0.5 mg IM (1 mg/mL).
• Pediatric: 0.01 mg/kg up to 0.3–0.5 mg.
• Infusion (refractory): 1–10 mcg/min titrated.
• Do not delay epinephrine for IV access or antihistamines.

Algorithm

1. Perform immediate ABC assessment, obtain focused vital signs/monitoring, and treat any time-critical physiologic threat.
2. Use focused history and examination to classify the mechanism and identify the dangerous alternative that must be excluded.
3. Order only tests that confirm the syndrome, quantify severity, identify a treatable complication, or change disposition.
4. Give mechanism-specific therapy and define the expected response endpoint before the next intervention.
5. Reassess trajectory and choose discharge, observation, admission, transfer, or procedure based on residual risk.
6. Apply the topic-specific branch 'Adult' when appropriate: 0.3–0.5 mg IM (1 mg/mL).
7. Apply the topic-specific branch 'Pediatric' when appropriate: 0.01 mg/kg up to 0.3–0.5 mg.
8. Implementation check: Do not delay epinephrine for IV access or antihistamines.

Clinical Synopsis & Reasoning

Anaphylaxis is life‑threatening; give intramuscular epinephrine immediately in the mid‑anterolateral thigh, repeat as needed, and manage airway/respiration/circulation with adjuncts and observation.

The central clinical task in Anaphylaxis — Recognition & Epinephrine First is to recognize the time-sensitive physiologic threat, stabilize it, and then use the smallest set of high-yield tests to identify the mechanism that changes immediate treatment or disposition. Begin with airway, breathing, circulation, mental status, temperature, bedside glucose when relevant, and a focused exposure or medication history. The emergency diagnosis is often provisional at first; the plan must be safe while uncertainty remains.

Escalation findings include threatened airway, refractory hypoxemia, shock, malignant dysrhythmia, active major hemorrhage, seizure, severe agitation that prevents safe care, rapidly progressive neurologic deficit, or a toxin/infection process likely to deteriorate before confirmatory testing returns. When one of these is present, stabilization and diagnosis proceed in parallel. A normal early test does not overrule dangerous physiology, and a familiar diagnosis should not explain away a new objective abnormality without reassessment.

The differential should be organized by mechanisms that require different early treatments. For cardiopulmonary complaints, separate obstructive, pump, volume, vascular, infectious, toxic, and metabolic causes. For altered mental status or behavioral presentations, distinguish primary psychiatric disease from intoxication, withdrawal, hypoxia, infection, endocrine/metabolic disease, neurologic injury, and medication effects. For allergic or toxic syndromes, identify the pathway that determines the antidote or rescue therapy rather than relying on a nonspecific symptom list.

Testing should answer one of four questions: Is there an immediately reversible threat? Which mechanism is most likely? How severe is it? What complication changes disposition? Point-of-care ultrasound, ECG, targeted laboratory testing, and focused imaging are valuable because they can shorten the interval between question and action. Broad testing without a decision attached to the result increases false positives and can delay treatment.

Topic-specific decision branches help convert the presentation into an action plan. When the relevant branch is Adult, the practical implication is 0.3–0.5 mg IM (1 mg/mL). When the relevant branch is Pediatric, the practical implication is 0.01 mg/kg up to 0.3–0.5 mg. When the relevant branch is Infusion (refractory), the practical implication is 1–10 mcg/min titrated. When the relevant branch is Autoinjector options, the practical implication is 0.1, 0.15, 0.3 mg. When the relevant branch is Beta‑blocker patient, the practical implication is Add glucagon 1–2 mg IV. A practical implementation point from the source article is: Do not delay epinephrine for IV access or antihistamines. Document suspected triggers and provide avoidance counseling. These branches are most useful when interpreted as decision points rather than memorized facts: each should answer whether to resuscitate, give a specific antidote or medication, obtain urgent imaging/procedure, consult a specialty service, observe, or discharge.

Reassessment is a core emergency intervention. Repeat vital signs, mental status, perfusion, respiratory effort, pain, ECG findings, bedside ultrasound, or relevant laboratory values after the first meaningful treatment. Failure to improve should trigger reconsideration of diagnosis, treatment delivery, dose, hidden complication, or need for definitive source control rather than automatic repetition of the same therapy.

Disposition is part of the diagnostic process. Patients with unstable physiology, recurrent symptoms after initial stabilization, need for continuous titration or invasive treatment, inability to complete essential follow-up, or a condition with meaningful short-term deterioration risk require observation, admission, or transfer. Discharge requires a coherent diagnosis or safe working diagnosis, symptom control, explicit return precautions, and an actionable follow-up plan.
Special populations require different thresholds. Older adults, pregnant patients, children, immunocompromised patients, people with renal or hepatic dysfunction, and patients taking anticoagulants or cardioactive medications may present atypically and may tolerate physiologic stress poorly. A treatment dose or discharge pathway that is appropriate for a healthy adult may be unsafe in a patient with limited reserve. Medication reconciliation should therefore be treated as diagnostic data, not administrative housekeeping.

Communication during transitions is a safety intervention. The receiving team or outpatient clinician should know what was treated empirically, what dangerous diagnosis was considered, which tests remain pending, what treatment response occurred, and what finding would trigger escalation. When a patient is transferred, do not allow paperwork or imaging completion to delay stabilization. When a patient is discharged, avoid vague instructions such as 'return if worse'; name the specific symptoms and time window that should prompt immediate return.

Treatment Strategy & Disposition

Treatment for Anaphylaxis — Recognition & Epinephrine First should follow the management priority contained in the topic itself: Anaphylaxis is life‑threatening; give intramuscular epinephrine immediately in the mid‑anterolateral thigh, repeat as needed, and manage airway/respiration/circulation with adjuncts and observation. Relevant therapeutic tools are summarized below, but the clinical indication matters more than the presence of an option in a table. Epinephrine IM has a role in first-line treatment for anaphylaxis; repeat as clinically needed and is limited by no absolute contraindication in life-threatening anaphylaxis. Isotonic crystalloid has a role in treat distributive shock/hypotension and is limited by reassess frequently. Albuterol has a role in adjunct for persistent bronchospasm and is limited by does not replace epinephrine. H1 antihistamine has a role in adjunct for pruritus/urticaria after stabilization and is limited by does not treat shock or airway edema.

Treat the most dangerous reversible physiology first. Airway support, oxygenation/ventilation, hemorrhage control, antidote administration, epinephrine, IV calcium, vasopressors, rapid source control, or other rescue therapy should not be postponed merely to complete a diagnostic checklist. Once the patient is stable enough for a deliberate pathway, narrow therapy to the most likely mechanism and discontinue empiric treatments that no longer have an indication.

The first treatment should have a measurable endpoint. Examples include improved perfusion, narrower QRS, rising blood pressure, reduced work of breathing, symptom control, normalized glucose, reduced potassium, cessation of bleeding, or improved mental status. Reassess quickly enough to catch treatment failure before deterioration is obvious. When response is poor, verify delivery and dose, reopen the differential, and seek definitive treatment rather than stacking low-yield interventions.

Medication risk is part of emergency care. Renal/hepatic function, pregnancy, age, QT/QRS effects, bleeding risk, drug interactions, and prior adverse reactions may alter the safest choice. Adjunctive drugs should not displace therapies that change survival or organ risk—for example, antihistamines should not delay epinephrine in anaphylaxis and symptomatic treatment should not delay antidote or source control.

Disposition should match residual risk after treatment, not simply the improvement from the patient's worst point. Recurrent anaphylaxis, ongoing bleeding, persistent dysrhythmia risk, need for vasopressor/oxygen titration, severe intoxication, unsafe behavioral state, or uncertain source control usually requires monitored care. Discharge is appropriate only when the patient has a stable trajectory, understands return precautions, and can complete the next step in care.
Before the episode is considered complete, close the loop on prevention. That may mean an epinephrine prescription and allergy referral, medication changes after hyperkalemia, infection source follow-up, GI endoscopy planning, substance-use treatment, or a safer chronic pain plan. Emergency treatment is strongest when it prevents the next crisis rather than only normalizing the current vital signs.

Epidemiology / Risk Factors

• Incidence varies by age, comorbidity, medication and exposure patterns, but emergency risk is determined primarily by current physiology and trajectory.
• High-risk populations may present atypically, so age, pregnancy, immune status, renal function, and limited physiologic reserve should lower the threshold for reassessment.

Investigations

Epinephrine Dosing

Pharmacology

Prognosis / Complications

• Outcome depends heavily on recognition of dangerous physiology, speed of mechanism-specific treatment, and early identification of complications.
• A transient response to treatment does not guarantee low risk; recurrence and treatment half-life should influence observation and disposition.
• Failure of the expected trajectory should trigger diagnostic reassessment and escalation rather than routine repetition of low-yield therapy.

Patient Education / Counseling

• Explain the working diagnosis, what dangerous alternatives were considered, and why the current disposition is safe.
• Give explicit return precautions tied to recurrence, breathing difficulty, syncope, bleeding, worsening mental status, fever/shock, dysrhythmia symptoms, or other topic-specific danger signs.
• Review medication dosing and the role of rescue therapy using teach-back when the plan is complex.
• Arrange time-defined follow-up when the emergency visit does not complete definitive etiologic evaluation.

Notes

Use the structured sections above as a clinical reference, not as a rigid protocol. Individual management for Anaphylaxis — Recognition & Epinephrine First depends on age, pregnancy status when relevant, organ function, comorbidity, anatomy, contraindications, local resources, and patient preferences. Topic-specific branch points: Adult → 0.3–0.5 mg IM (1 mg/mL); Pediatric → 0.01 mg/kg up to 0.3–0.5 mg; Infusion (refractory) → 1–10 mcg/min titrated; Autoinjector options → 0.1, 0.15, 0.3 mg; Beta‑blocker patient → Add glucagon 1–2 mg IV. When physiology is unstable, treatment and diagnostic clarification should proceed in parallel rather than waiting for a perfect label.

References

1. AAAAI — Practice Parameters and Guidelines — Link